Samsung Biologics has secured 87.88% of the shares in the public tender offer for the global peptide contract development and manufacturing organization, Polypeptide Group. This exceeds the minimum acceptance condition of 66.7%, allowing the acquisition process to proceed smoothly.
On October 13, Samsung Biologics announced the preliminary results of the tender offer for Polypeptide Group shares, which took place from September 15 to October 12. The tender offer was conducted through its subsidiary, Samsung Peptides, established specifically for the acquisition.
The tender offer targeted a total of 33,016,411 shares, excluding treasury shares, at a price of 44.31 Swiss francs per share.
According to the interim tally, a total of 29,014,418 shares were tendered, including all 18,375,000 shares held by Draupnir Holding, the existing largest shareholder. This represents 87.88% of the shares being offered, or 87.59% of the total issued shares.
Samsung Biologics had set a condition that at least 66.7% of the shares must be tendered for the transaction to be accepted. The current participation rate significantly exceeds this threshold, fulfilling a key requirement for the acquisition.
The company plans to announce the confirmed interim results on October 16, following verification by an independent auditor. An additional bidding period will be held from October 19 to 30, after which the company will seek regulatory approvals from authorities in Europe, India, Australia, and Brazil. Payment will be made within ten trading days after receiving the necessary approvals.
In July, Samsung Biologics announced the acquisition agreement with Polypeptide Group, with a maximum acquisition price of approximately 1.46 billion Swiss francs (about 2.7 trillion won), aiming to complete the final acquisition by the end of November.
Once the acquisition is finalized, Samsung Biologics will expand its contract development and manufacturing organization (CDMO) services into the peptide sector, in addition to its existing antibody drugs, messenger RNA (mRNA), and antibody-drug conjugate (ADC) businesses. The company aims to diversify its portfolio and secure long-term growth drivers.
Peptides are gaining attention as key ingredients in treatments for diabetes and obesity. The global obesity treatment market is expected to grow to as much as $150 billion (about 200 trillion won) by 2035, driven by surging demand and expanded indications. Additionally, demand for peptide-based therapies is anticipated to increase.
A Samsung Biologics representative stated, "We will maximize business synergies by combining our large-scale production facility design and operational expertise with Polypeptide Group's peptide development and production technologies. We are also considering expanding production facilities to meet customer demand as the peptide market grows."
On October 13, Samsung Biologics announced the preliminary results of the tender offer for Polypeptide Group shares, which took place from September 15 to October 12. The tender offer was conducted through its subsidiary, Samsung Peptides, established specifically for the acquisition.
The tender offer targeted a total of 33,016,411 shares, excluding treasury shares, at a price of 44.31 Swiss francs per share.
According to the interim tally, a total of 29,014,418 shares were tendered, including all 18,375,000 shares held by Draupnir Holding, the existing largest shareholder. This represents 87.88% of the shares being offered, or 87.59% of the total issued shares.
Samsung Biologics had set a condition that at least 66.7% of the shares must be tendered for the transaction to be accepted. The current participation rate significantly exceeds this threshold, fulfilling a key requirement for the acquisition.
The company plans to announce the confirmed interim results on October 16, following verification by an independent auditor. An additional bidding period will be held from October 19 to 30, after which the company will seek regulatory approvals from authorities in Europe, India, Australia, and Brazil. Payment will be made within ten trading days after receiving the necessary approvals.
In July, Samsung Biologics announced the acquisition agreement with Polypeptide Group, with a maximum acquisition price of approximately 1.46 billion Swiss francs (about 2.7 trillion won), aiming to complete the final acquisition by the end of November.
Once the acquisition is finalized, Samsung Biologics will expand its contract development and manufacturing organization (CDMO) services into the peptide sector, in addition to its existing antibody drugs, messenger RNA (mRNA), and antibody-drug conjugate (ADC) businesses. The company aims to diversify its portfolio and secure long-term growth drivers.
Peptides are gaining attention as key ingredients in treatments for diabetes and obesity. The global obesity treatment market is expected to grow to as much as $150 billion (about 200 trillion won) by 2035, driven by surging demand and expanded indications. Additionally, demand for peptide-based therapies is anticipated to increase.
A Samsung Biologics representative stated, "We will maximize business synergies by combining our large-scale production facility design and operational expertise with Polypeptide Group's peptide development and production technologies. We are also considering expanding production facilities to meet customer demand as the peptide market grows."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.